Plus Therapeutics (PSTV) News Today → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free PSTV Stock Alerts $2.14 -0.02 (-0.93%) (As of 05/24/2024 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18, 2024 | finanznachrichten.dePlus Therapeutics Inc.: Plus Therapeutics Announces New Employment Inducement GrantsMay 17, 2024 | globenewswire.comPlus Therapeutics Announces New Employment Inducement GrantsMay 16, 2024 | msn.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finance.yahoo.comPlus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...May 15, 2024 | sfgate.comPlus: Q1 Earnings SnapshotMay 15, 2024 | markets.businessinsider.comPlus Therapeutics Inc. Q1 Loss Decreases, Beats EstimatesMay 15, 2024 | globenewswire.comPlus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 13, 2024 | globenewswire.comPlus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024May 12, 2024 | uk.investing.comPlus Therapeutics CEO buys $25,000 in company stockMay 11, 2024 | insidertrades.comAndrew John Hugh Macintyr Sims Acquires 4,902 Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) StockMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)May 9, 2024 | globenewswire.comPlus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE TrialMay 8, 2024 | globenewswire.comPlus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE TrialApril 22, 2024 | finance.yahoo.comMicro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of DefenseApril 22, 2024 | globenewswire.comPlus Therapeutics Receives $3 Million Award Recommendation from the United States Department of DefenseApril 19, 2024 | finance.yahoo.comPlus Therapeutics, Inc. (PSTV)April 9, 2024 | finance.yahoo.comNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamApril 9, 2024 | globenewswire.comNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.March 27, 2024 | finance.yahoo.comPlus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferenceMarch 25, 2024 | finance.yahoo.comPlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell DiagnosticMarch 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry TailwindsMarch 11, 2024 | finance.yahoo.comPlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal MetastasesMarch 7, 2024 | finance.yahoo.comPlus Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 7, 2024 | finance.yahoo.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | finance.yahoo.comQ4 2023 Plus Therapeutics Inc Earnings CallMarch 5, 2024 | investorplace.comPSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023March 5, 2024 | globenewswire.comPlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsFebruary 29, 2024 | msn.comIMUNON stock rallies 19% on early results for COVID-19 vaccineFebruary 27, 2024 | finance.yahoo.comPlus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024February 21, 2024 | morningstar.comPlus Therapeutics Inc PSTVDecember 18, 2023 | finanznachrichten.dePlus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024December 18, 2023 | finance.yahoo.comPlus Updates Financial and Cash Guidance for 2024December 12, 2023 | finance.yahoo.comPlus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker AnalysesNovember 29, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)November 20, 2023 | msn.comFortress Biotech, Plus Therapeutics among healthcare moversNovember 20, 2023 | finance.yahoo.comPlus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader WebinarNovember 15, 2023 | finance.yahoo.comPlus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023November 3, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Geron (GERN), Silk Road Medical (SILK) and Plus Therapeutics (PSTV)November 3, 2023 | finance.yahoo.comPlus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal MetastasesNovember 1, 2023 | benzinga.comWhy Plus Therapeutics Stock Popped TodayNovember 1, 2023 | finanznachrichten.dePlus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsOctober 31, 2023 | finance.yahoo.comPlus Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsOctober 25, 2023 | finance.yahoo.comPlus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader WebinarOctober 23, 2023 | finance.yahoo.comPlus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023October 9, 2023 | finance.yahoo.comPlus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in OctoberSeptember 19, 2023 | finance.yahoo.comTargeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSESeptember 15, 2023 | finance.yahoo.comDirector Howard Clowes Buys 6,993 Shares of Plus Therapeutics IncSeptember 11, 2023 | markets.businessinsider.comJonesTrading Sticks to Its Buy Rating for Plus Therapeutics (PSTV)September 11, 2023 | msn.comPlus Therapeutics gets $1.9M advance payment from CPRITSeptember 11, 2023 | finance.yahoo.comPlus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. PSTV Media Mentions By Week PSTV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTV News Sentiment▼1.890.83▲Average Medical News Sentiment PSTV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTV Articles This Week▼11▲PSTV Articles Average Week Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PetVivo News Today Sintx Technologies News Today STRATA Skin Sciences News Today Biotricity News Today NEXGEL News Today Microbot Medical News Today NeuroMetrix News Today Vivos Therapeutics News Today PAVmed News Today Meihua International Medical Technologies News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTV) was last updated on 5/27/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeNew Options need New Trading StrategiesNetpicks$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyJust $9 for a Year of Winning Market InsightsBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.